The drive for the new generation of vaccine therapies has precipitated a concurrent need for new and improved adjuvantation/delivery systems for these new vaccines. This new international conference will focus on updating the community on new adjuvant/delivery systems/technologies associated with developing modern vaccines strategies and vaccine research. There is now an urgent need for the development of these potent and safe adjuvants and delivery systems and MVADS 2019 will offer researchers a fresh forum to discuss this important topic in detail.

MVADS 2019 will be of interest to researchers/contributors from academic programs, industrial, governmental and regulatory groups.

SCIENTIFIC ADVISORY PANEL

Conference Chairman: Martin Bachmann (Inselspital, Bern, Switzerland / University of Oxford, Oxford, UK)

Edmond J. Remarque (BPRC, Rijswijk, The Netherlands)
Dennis Christensen (Statens Serum Institut, Copenhagen, Denmark)
Erik Lindblad (CRODA Denmark, Frederikssund, Denmark)
Mannmohan Singh (Takeda Vaccines Inc., Cambridge, Massachusetts, USA)
Derek O’Hagan (GSK, Rockville, Maryland, USA)
Virgil Schiljns (Wageningen University, The Netherlands)
Burkhard Becker (University of Zurich, Zurich, Switzerland)
Maria Lazaro (SEPPIC, Paris, France)
Chris Fox (IDRI, Seattle, USA)
Karl Ljungberg (Eurocine Vaccines AB, Solna, Sweden)
Stefan Jungbluth (EVI, Heidelberg, Germany)
Jeffrey A. Hubbell (University of Chicago, Chicago, Illinois, USA)

Behazine Combadiere (Cinity-Paris, Paris, France)
Ken Ishii (IMS/University of Tokyo, Tokyo, Japan)
Ofer Levy (Boston Children’s Hospital/Harvard Medical School, Boston, Massachusetts, USA)
Jean Haensler (Sanofi Pasteur, Marcy L’Etoile, France)
Matthew Heath (Bencard Adjuvant Systems, Worthing, West Sussex, UK)
Markus Clemenz (Verapido Medical GmbH, Villingen-Schwenningen, Germany)
Alessandro Manenti (VisMederi S.r.l., Siena, Italy)
Tobias Kamphuis (Janssen Vaccines, Leiden, The Netherlands)
Bror Morein (Swedish Agriculture University, Uppsala, Sweden)
Edward Lavelle (Trinity College Dublin, Dublin, Ireland)

CONFERENCE SCOPE

Scientific Sessions:
Mechanistic Interpretations · Delivery · Formulation & Design · Modern Vaccines & Adjuvants · Safety · Regulation · Future Developments
SESSION 1: OPENING PLENARY SESSION

Moderator: Martin Bachmann
(Inselspital, University of Bern, Bern, Switzerland)

‘Improved adjuvants and delivery systems: A public health imperative’
Martin Friede
(WHO, Geneva, Switzerland)

‘Deep learning of vaccine adjuvant by machine and immunology’
Ken Ishii
(IMS/University of Tokyo, Tokyo, Japan)

‘NHP models for vaccines, adjuvants and delivery systems’
Ed Remarque
(BPRC, Rijswijk, The Netherlands)

Coffee Break & Poster Set-Up

SESSION 2: IMMUNOLOGY – I

Moderator: Ken Ishii
(IMS/University of Tokyo, Tokyo, Japan)

‘Versatile nanoparticle quillaja adjuvant promotes both Th1 and Th2 responses to viral and bacterial antigens’
Bror Morein
(Swedish Agriculture University, Uppsala, Sweden)

‘An update on CAF01™ and the depot-or-not controversy revisited’
Dennis Christensen
(Statens Serum Institut, Copenhagen, Denmark)

‘The importance of IgA in protection against norovirus and influenza infections’
Sean Tucker
(Vaxart Inc., South San Francisco, California, USA)

‘Robust immunogenic response induced by highly transient Salmonella’
Siegfried Hapfelmeier
(University of Bern, Bern, Switzerland)

Lunch Break & Posters

SESSION 3: IMMUNOLOGY – II

Moderator: Bror Morein
(Swedish Agriculture University, Uppsala, Sweden)

‘CAF08b a novel liposomal adjuvant which induces IgG2a class switching by acting directly on B cells’
Gabriel Pedersen
(Statens Serum Institut, Copenhagen, Denmark)

‘Adjuvants targeting STING and inflammasomes for enhanced cellular immunity’
Edward Lavelle
(Trinity College Dublin, Dublin, Ireland)

‘Mucosal immunity evaluation for FLU vaccine’
Alessandro Manenti and Emanuele Montomoli
(VisMederi S.r.l., Siena, Italy)

‘T cell vaccination and immune regulation in cancer patients’
Daniel E. Speiser
(University of Lausanne, Epalinges, Switzerland)

Tea Break & Posters

SESSION 4: VACCINES DEVELOPMENTS

Moderator: Edward Lavelle
(Trinity College Dublin, Dublin, Ireland)

‘Pathogens engineer tolerance: Can immune-engineered vaccines outsmart them?’
Annie S. De Groot
(EpiVax, Providence, Rhode Island, USA)

‘Can the intranasal NanoVax™ adjuvant platform solve the enigma of suboptimal efficacy observed from intramuscular respiratory vaccines? RSV and flu vaccines revisited’
Ali Fattom
(BlueWillow Biologics, Ann Arbor, Michigan, USA)

‘Development of a vaccine against Type II diabetes’
Elisa Rösti
(Inselspital, University of Bern, Bern, Switzerland)

‘Developing adjuvants for animal vaccines: What do we have to consider?’
Jishu Shi
(Kansas State University, Manhattan, Kansas, USA)

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 23rd August 2019. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 23rd August 2019
SESSION 5: TECHNOLOGY, PLATFORMS & DELIVERY

Moderator: Dennis Christensen
(Statens Serum Institut, Copenhagen, Denmark)

‘Reprogramming the adjuvant properties of aluminum oxyhydroxide with nanoparticle technology’
Mark T. Orr, Amit P. Khandhar and Christopher B. Fox
(1 Infectious Disease Research Institute, Seattle, Washington, USA; 2 University of Washington, Seattle, Washington, USA)

‘Tailor-made vaccine delivery using self-assembling protein nanoparticles (SAPNs)’
Peter Burkhard
(Alpha-O Peptides AG, Riehen, Switzerland)

‘Glycosylation of VLPs: A platform for glycoconjugate vaccine production’
Timothy G. Keys, Michael Wetter, Chia-wei Lin, Hanne L.P. Tytgat, Christoph Rutschmann, Martin Bachmann, Emma Slack-Wetter and Markus Aebi
(1 Institute of Microbiology, ETHZ, Zurich, Switzerland; 2 Functional Genomics Center Zurich (FGCZ), Switzerland; 3 Department of Immunology, Inselspital, Bern, Switzerland; 4 Institute of Food, Nutrition and Health Science, ETH Zurich, Switzerland)

‘Formulation and delivery augmentations for enhanced expression of gene-based immunotherapeutics’
Katherine Schultheis
(Inovio Pharmaceuticals, Inc., San Diego, California, USA)

SESSION 6: SKIN IMMUNIZATION

Moderator: To be confirmed

‘Efficacy of an alpha-D-glucan nanoparticle adjuvant for intradermal immunization’
Harm HogenEsch, Juan Hernandez, Fangjia Lu and Yung-Yi Mosley
(College of Veterinary Medicine, Purdue University, West Lafayette, Indiana, USA)

‘Adjuvanted dissolvable microneedle patches’
Anne Moore
(University College Cork, Cork, Ireland)

‘Shallow and standardized ex vivo human skin injections of large single volumes of tissue dye with Dermaject® intradermal injection device’
Markus Clemen, Sandra Schulz, Nadine Landler-Gärtner, Claudia Hummel, Steffen Baumeister, Jörg Kalla, Roland Zengerle and Alfons Dehé
(1 Hahn-Schickard Gesellschaft, Villingen-Schwenningen, Germany; 2 Schweizwald-Baar Klinikum, Villingen-Schwenningen, Germany; 3 Praxis für Plastische und Ästhetische Chirurgie, Villingen-Schwenningen, Germany; 4 Verapido Medical GmbH, Villingen-Schwenningen, Germany)

‘Skin vaccination with 1/6 standard dose of inactivated split influenza vaccine using the Vaxxas high-density microarray patch (HD-MAP) results in comparable immune responses to conventional full-dose intramuscular injection: Results from a phase I clinical study’
Germain J. Fernando
(Vaxxas Pty Ltd, Translational Research Institute, Brisbane, Queensland, Australia)

SESSION 7: ADJUVANTS I

Moderator: Ed Remarque
(BPRC, Rijswijk, The Netherlands)

‘Adjuvant systems production process: Current situation and technological perspective’
Veronique Henderickx
(GSK Vaccines, Rixensart, Belgium)

‘Mycrocrystalline tyrosine: A potent adjuvant for cancer vaccine’
Mona Mohsen
(Inselspital University of Bern, Bern, Switzerland)

‘Bencard adjuvant systems: Shaping modern vaccines’
Matthew Heath
(Bencard Adjuvant Systems, Worthing, West Sussex, UK)

‘A new form of aluminium phosphate adjuvant with enhanced protein adsorption: Adju-Phos Z®’
Laurent Duroux
(CRODA Denmark, Frederikssund, Denmark)

‘Property-activity analysis of engineered aluminium-based vaccine adjuvants and adjuvant-antigen complexes’
Bingbing Sun
(Department of Chemical Engineering, Dalian University of Technology, China)

SESSION 8: VACCINES DESIGN

Moderator: Mark Orr
(IDRI, Seattle, Washington, USA)

‘Age-specific adjuvants for precision vaccinology’
Ofer Levy
(Boston Children’s Hospital/Harvard Medical School, Boston, Massachusetts, USA)

‘Designing VLP-based vaccines for the treatment of peanut-allergy’
Martin Bachmann
(Inselspital University of Bern, Bern, Switzerland)

‘Application of RNA technology for vaccine design’
Christine Rueckert
(CureVac AG, Tuebingen, Germany)

‘Bacterial evolution: Friend or foe in vaccine design’
Emma Marie Caroline Slack
(ETHZ, Zurich, Switzerland)

‘Mucosal delivery with an outer membrane vesicle pertussis vaccine confers enhanced protection’
Gaurav Kanoija
(IntraVacc, Bithoven, The Netherlands)

‘Adjuvanted virosome VLP as flexible and potent universal vaccine platform for induction of systemic and mucosal immunity’
Mario Amacker, Toon Stegmann and Sylvain Fleury
(Myometics SA, Epalinges, Switzerland; Myometics B.V., Leiden, The Netherlands)
SESSION 9: ADJUVANTS II

Moderator: Erik Lindblad
(CRODA Denmark, Frederikssund, Denmark)

'Matrix-M1 adjuvant (administered in combination with our influenza nanoparticle vaccine) in stimulating potent antigen specific CD4+ T cell responses'
Vivek Shinde
(Novavax Inc., Gaithersburg, Maryland, USA)

'Adjuvant selection and characterization for a lipoprotein antigen-containing vaccine candidate'
Marie Garinot
(Sanofi Pasteur, Lyon, France)

'Quillaja Clonal Variants: A new source of highly purified QS-21'
Damian Hiley
(Desert King International, San Diego, California, USA)

'Characteristics of Montanide ISA 51 VG adjuvants designed for therapeutic vaccines, mechanisms of action and review of advanced clinical projects with the adjuvant'
Aude Puget and Maria Lazaro
(SEPPIC, Paris La Défense, Paris, France)

'Biodistribution of the vaccine adjuvant alhydrogel using 111/115in-doped aluminum oxyhydroxide'
Tullio V. F. Esposito1,2, Jacqueline C.Y. Lai3,4, Patrick D. Hopkins3, Rahul Schneider1, Cristina Rodriguez-Rodriguez1,5,6, Camilla Foged2, Jan P. Dutz2, Katayoun Saatchi1* and Urs O. Hafeli1,2*
(1 University of British Columbia, Canada; 2 Department of Pharmacy, Faculty of Health and Medical Sciences, University of Copenhagen, Denmark; 3 Department of Dermatology and Skin Science, Faculty of Medicine, University of British Columbia, Canada; 4 Department of Physiology, Institute of Neuroscience and Physiology, University of Gothenburg, Sweden; 5 Department of Physics and Astronomy, Faculty of Science, University of British Columbia, Canada; 6 Centre for Comparative Medicine, University of British Columbia, Canada)

Coffee Break & Posters

SESSION 10: LATEBREAKERS SESSION

Moderator: To be confirmed

‘Immunogenicity and safety of the army liposome formulations containing QS-21 (ALFQ) in non-human primates’
Zoltan Beck1,2, Gary R. Matyas3, David E. Lanar4, Amritha Ramakrishnan2, Evelina Angov1, Renee M. Laird1,5 and Sheetij Dutta2
(1 U.S. Military HIV Research Program, Laboratory of Adjuvant and Antigen Research, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA; 2 Henry M. Jackson Foundation for the Advancement of Military Medicine, Bethesda, Maryland, USA; 3 Malaria Vaccine Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA; 4 Naval Medical Research Unit Six, Lima, Peru; 5 Department of Enteric Diseases, Naval Medical Research Center, Silver Spring, Maryland, USA)

‘HIV-1 Env V1V2-specific immune responses induced by Immunization with self-assembling protein nanoparticles’
Christopher P. Karch1,2, Peter Burkhardt3, Gary R. Matyas2 and Zoltan Beck1,2
(1 U.S. Military HIV Research Program, Henry M. Jackson Foundation for Military Medicine, Bethesda, Maryland, USA; 2 Laboratory of Adjuvant and Antigen Research, U.S. Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA; 3 Alpha-O Peptides, Riehen, Switzerland)

‘Combining automated vaccine formulation with data rich experimentation’
Patrick L. Ahl1, YingKai Liang2, William J. Smith1, Marie L. Dowd1 and Jeffrey T. Blue1
(1 Vaccine Drug Product Development; 2 Pharmaceutical Discovery, Merck & Co., Inc., West Point, Pennsylvania, USA)

Closing Remarks
Lunch & Departure

Latebreaker abstracts for oral presentation at MVADS 2019 are called for. Authors interested in submitting latebreaker oral abstracts should submit their abstracts directly to John Herriot at Meetings Management (MVADS 2019 Organizers).
Please email your latebreaker abstracts to jherriot@meetingsmgmt.u-net.com
Closing date for latebreaker submissions is Friday 23rd August 2019

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 23rd August 2019. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 23rd August 2019

* This provisional programme is correct at the time of publication. However the organizers reserve the right to make any alterations that may be required in the interests and integrity of the conference programme.
‘Novel recombinant BCG recruited M1 macrophage in mice infect mycobacteria H37Ra model: Implication for TB vaccine development’
Shiu-Ju Yang1, Yih-Yuan Chen1, Chih-Hao Hsu1, Jia-Ru Chang1 and Horng-Yunn Dou1
(1 National Institute of Infectious Diseases and Vaccinology, National Health Research Institutes, Zhunan, Miaoli, Taiwan; 2 Department of Biochemical Science and Technology, National Chiayi University, Chia-Yi, Taiwan)

‘Characterization of early immune events in the skin following transfollicular vaccination’
Simon Delandre1, Kai Schulze1, Andreas Müller2, Claus-Michael Lehr3 and Carlos A. Guzmán1
(1 Helmholtz-Zentrum für Infektionsforschung, Braunschweig, Germany; 2 Institute of Molecular and Clinical Immunology (IMKI), Magdeburg, Germany; 3 Helmholtz-Institute for Pharmaceutical Research Saarland (HIPS), Saarbrücken, Germany)

‘Evaluation of genotoxic and cytogenetic effects of papilomavirus L1 protein associated with saponins obtained from Agave sisalana Perrine (sisal)’
Roberta Fiusa Magnelli1, Rita de Cássia Stocco1, Pedro Ismael da Silva Junior2 and Ronaldo Zucatelli Mendonça1
(1 Laboratory of Genética, 2 Special Laboratory of Applied Toxinology, 3 Laboratory of Parasitology, Butantan Institute, Sao Paulo, Brazil)

‘GMMA platform for the development of effective multicomponent vaccines’
M.G. Aruta, R. Alfini, R. Di Benedetto, M. Carducci, O. Koeberling, A. Saul, F. Necchi and F. Micoli
(GSK Vaccines Institute for Global Health, Siena, Italy)

‘Toll like receptor 7/8 agonist-loaded nanoemulsion vaccine adjuvants for the enhanced cancer immunotherapy’
So hyun Kim, Hong Sik Shin, Sun-Young Kim and Yong Taik Lim
(SKKU Advanced Institute of Nanotechnology (SAINT), Department of Nano Engineering, and School of Chemical Engineering, Sungkyunkwan University, Suwon, Gyeonggi-do, Republic of Korea)

‘Detecting vaccine-induced antibodies binding to different forms of amyloid beta’
Delphine Knittel, Emma Fiorini, Valérie Giriens, Nathalie Chuard, Rakel Carpintero, Chiara Babolin, Andrea Pfeifer, Marie Kosco-Vilbois and Marija Vukicevic
(AC Immune SA, EPFL Innovation Park, Lausanne, Switzerland)

‘The development and characterization of EcML; MPL from recombinant E.coli, as a new vaccine adjuvant’
Da Hui Ha1, Choon Geun Lee1, Ye Ram Lee1, Jeong-Yoon Lee1, Chan Kyu Lee1, Seuk Keun Choi1, Seok Kyu Kim1 and Yeong Ok Baik1, Ji hyun Yang2, Quyen Thi Nguyen2, Eunjin Kim2 and Haryoung Poo2, Yu Hyun Ji1, 4 and Hak Suk Chung1
(1 Eubiologics Co., Ltd., Republic of Korea; 2 Korea Research Institute of Bioscience and Biotechnology (KRIIBB), Republic of Korea; 3 Korea Institute of Science and Technology (KIST), Republic of Korea; 4 School of Life Sciences and Biotechnology, Korea University, Republic of Korea)
REGISTRATION

Delegates should register for MVADS 2019 by completing the form provided on the back page of this brochure. The completed Conference Registration Form plus payment (in £ Pounds Sterling) should be sent to the MVADS 2019 Conference Manager – Caroline Sumner at Meetings Management. The MVADS 2019 Conference Registration Desk will be open from 8.00am on Monday 9th September 2019.

Delegates can also register securely on-line at: www.meetingsmanagement.com/mvads_2019

VENUE & ACCOMMODATION

MVADS 2019 will be held at:
Inselspital, Universitätsspital, Bern, Switzerland

Accommodation: there are numerous hotels in Bern to suit most budgets. For information details on accommodation in Bern and other useful information, please visit:
https://www.bern.com/

Please note that the MVADS 2019 conference organizers will not be recommending any specific hotels in Bern.

September is a busy time in Bern and it is recommended that MVADS 2019 delegates book their accommodation without delay.

PUBLICATION

A USB storage device containing the final programme and abstracts of all presentations, oral and poster, will be distributed to delegates when they register at the conference.

TABLE TOP EXHIBITION

Table Top Exhibition space is available at the meeting. Exhibitors can showcase their products or services by reserving a table top exhibit. The exhibit area will be located where all refreshments breaks will be taken to ensure maximum traffic of conference delegates. If you are registering for the conference, you can reserve a table for £1500. If you do not wish to attend the conference sessions, you can reserve a table for £2500 (includes admission to all meals/receptions by one company representative).

PLEASE NOTE: If you wish to have additional representatives on your table top exhibit there will be an additional charge for catering levied per head.

DELEGATE PACK INSERT SERVICE

Company literature/brochures/conference brochures may be distributed to delegates as part of the documentation issued on arrival/registration. One insertion in the MVADS 2019 delegate pack is priced at £450. Please make your booking and payment using the relevant section on the Delegates Registration Form on the back page of this brochure.

PLEASE NOTE: Literature for distribution to MVADS 2019 delegates is subject to approval by the conference organizers.

INSURANCE & CANCELLATION

The organizers cannot be held responsible for any personal accident or damage to their private property of participants at MVADS 2019. The organizers strongly urge participants to ensure they have adequate travel and personal insurance cover before they depart for the conference. The organizers cannot be held liable for any costs incurred should the conference be cancelled for any reason. Maximum notice of cancellation will be given by the organizers to all pre-registered delegates.

PROGRAMME

The MVADS 2019 Scientific Advisory Panel and the MVADS 2019 Conference Organizers reserve the right to alter any part of the published provisional conference programme if this is necessitated by any circumstances outside their control. All efforts will be made to keep any such changes to a minimum. The provisional programme published in the brochure was correct at the time of going to press.

CANNOT ATTEND?

If you and your colleagues are unable to attend the conference, the conference materials (abstract booklet, speaker handouts, late abstracts, attendee list, pack materials and literature) are available for purchase. While not intended as a substitute for actual attendance, these materials would at least provide a documentary record of the event and allow you to keep you or your organization’s library up to date. The cost of providing this non-attendee package is £395 (including postage and packing). To order this package from Meetings Management please use the relevant section in the Delegates Registration Form on the back page of this brochure.

ANY QUESTIONS?

For further information and assistance, please contact: Caroline Sumner, MVADS 2019 Conference Manager:

MVADS 2019 Conference Secretariat, Meetings Management
Forge Cottage, Bowhead Green, Godalming, Surrey GU8 6NW, United Kingdom.
Telephone: +44 (0)1483 427770 Fax: +44 (0)1483 428516
E-mail: csumner@meetingsmgmt.u-net.com

LATE-BREAKER ORAL AND POSTER ABSTRACTS

The Scientific Advisory Panel have set an extended deadline for Late-Breaker Oral and Poster Abstracts of Friday 23rd August 2019. Prospective authors should submit one page Word documents to the Conference Organizers (Meetings Management) for consideration.

Please send submissions for the attention of John Herriot by e-mail to: jherriot@meetingsmgmt.u-net.com

Late-Breaker Oral and Poster Abstracts should be submitted by Friday 23rd August 2019
Please tick appropriate boxes and write clearly in BLOCK CAPITALS or type.

Surname ........................................ First Name ........................................ Title ........................................
Organization ........................................ Address ........................................
..........................................................................................................................
..........................................................................................................................
..........................................................................................................................
..........................................................................................................................
Country ........................................ Telephone ........................................ Fax ........................................
E-mail (plain type or print): ........................................
If you are an EC business please state your VAT registration number: ........................................
Disabled (please state any special needs): ........................................ Special diet (please state requirements): ........................................

REGISTRATION FEES

<table>
<thead>
<tr>
<th>Speaker/Delegate Registration Fees: (Please tick appropriate section)</th>
<th>Amount Due (£ Sterling)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Speaker Registration (submitted oral/poster papers)</td>
<td>£650.00</td>
</tr>
<tr>
<td>Reduced Early Bird Registration</td>
<td>£775.00</td>
</tr>
<tr>
<td>Full Registration</td>
<td>£875.00</td>
</tr>
<tr>
<td>Student Registration</td>
<td>Price on application</td>
</tr>
</tbody>
</table>

Table Top Exhibits/Delegate Pack Inserts

<table>
<thead>
<tr>
<th>Table Top Exhibit</th>
<th>Amount Due (£ Sterling)</th>
</tr>
</thead>
<tbody>
<tr>
<td>If registering for one of the four options above</td>
<td>£1500.00</td>
</tr>
<tr>
<td>I am NOT registered to attend</td>
<td>£2500.00</td>
</tr>
</tbody>
</table>

For those Unable to Attend

<table>
<thead>
<tr>
<th>Set(s) of MVADS 2019 materials</th>
<th>Amount Due (£ Sterling)</th>
</tr>
</thead>
<tbody>
<tr>
<td>@ £395.00 (per set)</td>
<td></td>
</tr>
</tbody>
</table>

Total Amount Payable £

Registration fees include admission to all conference sessions, morning and afternoon refreshments and lunches on the 9th, 10th and 11th September 2019.

PAYMENT

<table>
<thead>
<tr>
<th>serene (Please tick appropriate)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>I enclose a cheque for £........... made payable to Meetings Management. (Delegates registering from outside the UK must ensure that cheques are drawn on a London Bank. Please quote MVADS 2019 on the reverse of the cheque.)</td>
<td></td>
</tr>
<tr>
<td>I have made a payment by bank transfer (quoting MVADS 2019 on the transfer documentation) to Barclays Bank, Barclays Business Centre, Guildford Branch, PO Box 33, Guildford, Surrey GU1 3AN, UK: UK Pounds Sterling Account: Meetings Management 0040614335 IBAN: GB11BUKB20323055917600 SWIFTBIC: BUKBGB22 US Dollar Account: Meetings Management 53209211 IBAN: GB18BUKB20323055917600 SWIFTBIC: BUKBGB22</td>
<td></td>
</tr>
</tbody>
</table>

All transfer charges must be paid by the sender. Delegates paying by this method are requested to send the Conference Manager a copy of the bank transfer. Payments made by bank transfer must have £15.00 added to the total. PLEASE NOTE THAT IT WILL NOT BE POSSIBLE TO PAY REGISTRATION FEES BY BANK TRANSFER AFTER FRIDAY 5TH JULY 2019. LATE PAYMENT AFTER FRIDAY 5TH JULY 2019 MUST BE MADE BY CREDIT CARD (VISA/MASTERCARD/AMEX).

<table>
<thead>
<tr>
<th>serene (Please tick appropriate)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>I would like to pay £............... by credit card (VISA/MasterCard/American Express only accepted).</td>
<td></td>
</tr>
<tr>
<td>Card no.</td>
<td>3 Digit Security Code (AMEX: 4 Digits)</td>
</tr>
<tr>
<td>Expiry Date</td>
<td>Registered Card Address</td>
</tr>
</tbody>
</table>

Please remember that any remittance sent but not received by the time of the conference must be paid again at the Registration desk: we will refund you after the conference. Cancellations received before Friday 5th July 2019 will be refunded in full less an administrative charge of £275 per person. Refunds will not be possible if a cancellation is received after Friday 5th July 2019. Substitutions can be made at any time prior to the conference. Please inform the Conference Manager of any changes. We strongly advise that delegates purchase travel insurance to cover any unforeseen circumstances and protect against loss of hotel deposits and registration fees.

Signature ........................................ Date ........................................

PLEASE RETURN THIS FORM TO:

MVADS 2019 CONFERENCE SECRETARIAT, MEETINGS MANAGEMENT
Forge Cottage, Bowlhead Green, Godalming, Surrey GU8 6NW, United Kingdom
Conference Manager: Caroline Sumner Telephone: +44 (0)1483 427770 E-mail: csumner@meetingsmgmt.u-net.com

SECURE ON-LINE REGISTRATION IS NOW OPEN AT: www.meetingsmanagement.com/mvads_2019